0.44 USD
↗ 0.08 (23.55%)LIVE (AS OF 01:47 PM EDT)
Neumora Therapeutics, Inc. Common Stock
NMRANASDAQ • USD
Market: OPEN
Neumora Therapeutics, Inc. Common Stock (NMRA) trades at $0.44 per share. Both sides of the analysis point lower: technicals flash "Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest NMRA is trading at a discount to its peers, earning an "Attractively Valued" rating.
Technical & fundamental data as of Oct 14, 2026.
Open?$0.37
High?$0.45
Low?$0.35
Prev. Close?$0.35
Volume?5.0M
Avg. Volume?1.9M
VWAP?$0.42
Rel. Volume?2.67x
Bid / Ask
Bid?$0.37 × 400
Ask?$0.44 × 400
Spread?$0.07
Midpoint?$0.41
Valuation & Ratios
Market Cap?65.8M
Shares Out?187.9M
Float?81.8M
Float %?44.2%
P/E Ratio?N/A
P/B Ratio?1.48
EPS?-$1.13
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Employees
63
Market Cap
66.6M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2023-09-15
Address
260 ARSENAL PLACE, SUITE 1
WATERTOWN, MA 02472
Phone: (857) 760-0900
WATERTOWN, MA 02472
Phone: (857) 760-0900
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?50
Short Sent.?46
Piotroski F-Score?0/9Weak
Altman Z-Score?-18.46Distress
Confidence?54%Low
Short InterestElevated
Short % of Float?8.18%Elevated
Short Interest?6.7M
Days to Cover?2.7
Free Float81.8M
Avg Daily Volume2.5M
Settlement Date2026-09-30
Financial Health
Current Ratio?4.50Strong
Quick Ratio?4.50Strong
Cash Ratio?4.21Strong
Debt/Equity?1.19Moderate
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?1.48CHEAP▾
Peers100
S&P87
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-0.0CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-477.9%WEAK▾
S&P3
ROA?-169.9%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-180520000
Enterprise Value?$1.8M
Fundamentals ratios updated end of day